<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03851575</url>
  </required_header>
  <id_info>
    <org_study_id>H-18028566</org_study_id>
    <nct_id>NCT03851575</nct_id>
  </id_info>
  <brief_title>Accelerated Treatment of Endocarditis</brief_title>
  <acronym>POETII</acronym>
  <official_title>Accelerated Treatment of Endocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordsjaellands Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lund University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Existing guidelines recommend a duration of antibiotic treatment of endocarditis of 4-6 weeks
      with one or two types of intravenously administered antibiotics. The long hospitalization
      increases several risks for the patient, including mental strain and increased loss of
      function. Furthermore, it poses a significant burden on health systems. Current guidelines
      fail to use available data collected from patients (echo, temperature, CRP, leukocytes,
      procalcitonin etc.) to determine duration of treatment. A strategy including these data in
      treatment algorithms ensures an individualized treatment, targeting the patient's course and
      response to treatment. Thus, the purpose of this open-label, prospective, non-inferiority,
      RCT study is to investigate the safety and effectiveness of shortening treatment of
      endocarditis based on the individual patient's initial treatment response, sampling 750
      patients, approx. 200 patients with each type of bacteria (Streptococci; Enterococcus
      faecalis; Staphylococcus aureus). Interim analysis will be conducted when 150 patients have
      been included, to assess the frequency of the event rate and inclusion rate in order to
      adjust the intended size of the study population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Anticipated">December 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary composite endpoint</measure>
    <time_frame>6 monts after randomization</time_frame>
    <description>Number of patients with at least one of the following: Death (yes/no); Embolisms (yes/no); Bacteraemia with the same microorganism (yes/no), surgery not planned at randomization (yes/no).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 monts after randomization and after</time_frame>
    <description>Quality of life assessed by completing short version 36 (SF 36) version 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expenses</measure>
    <time_frame>6 monts after randomization</time_frame>
    <description>Expenses associated with hospitalization and treatment of the disease. I.E., expenses to admission, examinations and medicine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>6 monts after randomization</time_frame>
    <description>Duration of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>6 monts after randomization</time_frame>
    <description>Number of patients that die</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embolisms</measure>
    <time_frame>6 monts after randomization</time_frame>
    <description>Number of patients that have an embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteraemia with the same microorganism,</measure>
    <time_frame>6 monts after randomization</time_frame>
    <description>Number of patients that have Bacteraemia with the same microorganism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery not planned at randomization</measure>
    <time_frame>6 monts after randomization</time_frame>
    <description>Number of patients that have Surgery not planned at randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Infectious Endocarditis</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual guideline therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Accelerated arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Accelerated treatment of endocarditis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Accelerated treatment of endocarditis</intervention_name>
    <description>For the three main bacteria species we shorten the duration of antibiotic treatment</description>
    <arm_group_label>Accelerated arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual guideline therapy</intervention_name>
    <description>Usual guideline therapy</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients hospitalized and diagnosed with bacterial, left-sided endocarditis as
             determined by the department clinician responsible based on the revised Duke criteria.

          2. The patient may be included &lt;14 days after beginning of relevant antibiotic treatment.

          3. Left-sided endocarditis with one of the following microorganisms: Streptococci;
             Enterococcus faecalis; Staphylococcus aureus.

          4. Patients â‰¥ 18 years.

        Exclusion Criteria:

          1. Known / suspected immunocompetence (HIV, chemotherapy, prednisolone treatment (&gt; 20 mg
             / day)).

          2. Incapability to give informed consent for participation.

          3. Relapse Endocarditis (Endocarditis with the same bacteria within six months).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Bundgaard, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kasper K Iversen, MD</last_name>
    <phone>+4528712753</phone>
    <email>kasper.k.iversen@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Skejby Sygehus</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Wiggers, MD</last_name>
      <email>henrikwiggers@dadlnet.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henning Bundgaard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Bruun, MD</last_name>
      <email>n.eske.b@dadlnet.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hoslpital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasper Iversen</last_name>
      <email>kasper.iversen@dadlnet.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HillerÃ¸d Hospital</name>
      <address>
        <city>HillerÃ¸d</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels TÃ¸nder</last_name>
      <email>nito@0regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense Sygehus</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Gill, MD</last_name>
      <email>sabine.gill@dadlnet.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roskilde Sygehus</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanne Elming</last_name>
      <email>hei@regionsjaelland.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 3, 2018</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2019</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Kasper Iversen</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis, Subacute Bacterial</mesh_term>
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

